Synlogic announces positive phase 2 data demonstrating reduction in plasma phenylalanine levels in patients with phenylketonuria

Cambridge, mass., sept. 20, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical studies evaluating both synb1618 and synb1934, investigational synthetic biotic™ medicines for the treatment of phenylketonuria (pku).
SYBX Ratings Summary
SYBX Quant Ranking